End Stage Cancer clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    open to eligible people ages 18 years and up

    This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

    Santa Monica, California and other locations

Last updated: